Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Do you offer consolidation chemotherapy prior to durvalumab in locally advanced, unresectable NSCLC?

9
3 Answers

Mednet Member
Mednet Member
Medical Oncology · Indiana University School of Medicine

I do not offer consolidation chemotherapy to patients prior to durvalumab in patients with locally advanced, unresectable NSCLC. The PACIFIC trial was a randomized phase III trial that established the role of consolidation durvalumab after definitive chemoradiation for patients with stage III NSCLC....

In an early stage breast cancer post neoadjuvant chemotherapy, do you repeat ER/PR and HER2 status on the surgical specimen if there is residual disease?

3
5 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic Rochester

It can be more nuanced than always repeating all the receptors. If there is residual disease after NAC, and the cancer is grade 3, I do feel it is worthwhile to at least repeat HER2. After all, we have good options for reducing the risk of recurrent HER2+ disease in the residual disease after NAC se...

For low/intermediate essential thrombocythemia not on cytoreduction, would you temporarily cytoreduce in anticipation of surgery?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

First, I am going to answer this question with a question. What is low/intermediate essential thrombocytosis (ET)? I ask this question because we are living in the 21st century in the midst of the genomic era, and it is far past the time that we should be dwelling on phenotype instead of employing p...

For low/intermediate essential thrombocythemia not on cytoreduction, would you temporarily cytoreduce in anticipation of surgery?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

First, I am going to answer this question with a question. What is low/intermediate essential thrombocytosis (ET)? I ask this question because we are living in the 21st century in the midst of the genomic era, and it is far past the time that we should be dwelling on phenotype instead of employing p...

How do you counsel patients/families whose goals of care are clearly aligned with a comfort-focused, end-of-life approach, but who are hesitant to formally enroll in hospice?

2
4 Answers

Mednet Member
Mednet Member
Hospital Medicine · University of Tennessee Health Science Center

Hospice sounds like a 4-letter word to a lot of families! I find it important to distinguish the philosophy of comfort care vs. the benefit package associated with enrolling in hospice. Some people are able to be provided end-of-life comfort care without electing the hospice benefit, and that is fin...

How do the ALTTO trial findings influence your choice of adjuvant endocrine therapy (AI with or without ovarian function suppression versus SERM-based therapy) for patients with HR+/HER2+ early breast cancer?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Colorado Cancer Center

The major takeaway is that endocrine therapy works for HER2+ breast cancer, although the magnitude of the benefit may not be as large as for ER+/HER2- BC. Thus, OFS will contribute to efficacy in a way similar to that of the TEXT/SOFT trial. Because of the higher toxicity associated with OFS, the ab...

Would you give adjuvant radiation after complete resection of a small primary cutaneous follicular lymphoma of the scalp?

5
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Not a lot of data, but here goes. First, one has to go back decades in the literature to find series of patients with lymphoma rx'd with surgical resection alone. In general addition of RT improved outcome even when ostensibly resected with neg margins. With today's technology risk of additional RT ...

What are your top takeaways in Classical Hematology from ASH 2025?

2
5 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester School of Medicine and Dentistry

My top 3 takeaways in classical hematology:1) ITP - much controversy at the education program session about the draft 2025 guidelines, where TPO mimetic + steroids is going to be recommended in the front line. There does not appear to be compelling new data that supports the revision of this guideli...

What are your top takeaways in Classical Hematology from ASH 2025?

2
5 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester School of Medicine and Dentistry

My top 3 takeaways in classical hematology:1) ITP - much controversy at the education program session about the draft 2025 guidelines, where TPO mimetic + steroids is going to be recommended in the front line. There does not appear to be compelling new data that supports the revision of this guideli...

Do you routinely check serum phosphorus levels after IV iron therapy?

1
2 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

Only before and after FCM. I hold subsequent doses if phosphorus low. There is no need to monitor with the other formulations. For people needing multiple doses of IV iron (IBD, bariatric surgery, heavy uterine bleeding, angiodysplasia), I avoid FCM.